• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Effects of combined use of roxatidine and pirenzepine on gastric secretion in humans.

作者信息

Misawa T, Chijiiwa Y, Yoshida K, Tanaka A, Kabemura T, Fujishima H, Harada N, Nawata H

机构信息

Third Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka.

出版信息

Fukuoka Igaku Zasshi. 1990 Jul;81(7):242-6.

PMID:1976580
Abstract

We examined the effects of the combined use of H2-receptor antagonist (roxatidine) and muscarinic receptor antagonist (pirenzepine) by oral administration on gastric juice and acid secretion in humans. The volume, pH level, and acidity of gastric juice were determined in the sample collected at 9:00 AM 10 hr after either the oral administration of 150 mg of roxatidine or the combined administration of 150 mg of roxatidine and 50 mg of pirenzepine. Significant decrease in volume and acidity and increase in pH were observed in both roxatidine group and combined group compared with control placebo group, but significant difference were not observed in gastric pH and acidity between roxatidine group and combined group. The volume of gastric juice was decreased significantly by the combined administration in comparison with the sole administration of roxatidine. Consequently, the combined oral administration of the two agents was considered to be more effective than the sole administration of roxatidine for clinical cases which require stronger suppression of gastric secretion at the night.

摘要

相似文献

1
Effects of combined use of roxatidine and pirenzepine on gastric secretion in humans.
Fukuoka Igaku Zasshi. 1990 Jul;81(7):242-6.
2
Radiographic assessment of nocturnal gastric juice secretion after administration of roxatidine acetate hydrochloride.
Clin Ther. 1991 Jan-Feb;13(1):22-4.
3
[The effect of oral administration of roxatidine acetate hydrochloride 3 hours prior to the operation on pH and volume of gastric juice].术前3小时口服盐酸罗沙替丁对胃液pH值和胃液量的影响
Masui. 1991 Mar;40(3):451-3.
4
Do anticholinergics interact with histamine H2 receptor antagonists on night intragastric acidity in active duodenal ulcer patients?抗胆碱能药物与组胺H2受体拮抗剂对活动性十二指肠溃疡患者夜间胃内酸度有相互作用吗?
Am J Gastroenterol. 1988 Dec;83(12):1371-5.
5
A histamine H2 receptor antagonist, roxatidine, stimulates mucus secretion and synthesis by cultured rabbit gastric mucosal cells.组胺H2受体拮抗剂罗沙替丁可刺激培养的兔胃黏膜细胞分泌和合成黏液。
J Physiol Pharmacol. 1995 Dec;46(4):503-11.
6
Effect of the novel histamine H2-antagonist 5,6-dimethyl-2-[4-[3-(1- piperidinomethyl)phenoxy]-(z)-2-butenylamino]-4(1H)-pyrimidine dihydrochloride on histamine-induced gastric acid secretion in Heidenhain pouch dogs.新型组胺H2拮抗剂5,6-二甲基-2-[4-[3-(1-哌啶甲基)苯氧基]-(Z)-2-丁烯基氨基]-4(1H)-嘧啶二盐酸盐对海登海因小胃犬组胺诱导胃酸分泌的影响
Arzneimittelforschung. 1993 Aug;43(8):873-6.
7
Regular use of H2 blockers reduces the efficacy of roxatidine to control gastric pH and volume.
Can J Anaesth. 2005 Feb;52(2):166-71. doi: 10.1007/BF03027723.
8
Effect of a histamine H2-receptor antagonist, famotidine, on gastric secretion in healthy subjects.
Clin Ther. 1987;9(5):528-35.
9
The pharmacodynamics and pharmacokinetics of multiple doses of the new H2-receptor antagonist, roxatidine acetate, in healthy men.多次服用新型H2受体拮抗剂醋酸罗沙替丁在健康男性中的药效学和药代动力学。
Drugs. 1988;35 Suppl 3:53-64. doi: 10.2165/00003495-198800353-00011.
10
Single nocturnal doses of pirenzepine effectively inhibit overnight gastric secretion.夜间单次服用哌仑西平可有效抑制夜间胃酸分泌。
Hepatogastroenterology. 1985 Oct;32(5):240-2.

引用本文的文献

1
Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders.醋酸罗沙替丁。对其药效学和药代动力学特性及其在消化性溃疡疾病和相关病症中的治疗潜力的综述。
Drugs. 1991 Aug;42(2):240-60. doi: 10.2165/00003495-199142020-00006.